352 related articles for article (PubMed ID: 23099004)
1. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia.
Lybol C; Thomas CM; Blanken EA; Sweep FC; Verheijen RH; Westermann AM; Boere IA; Reyners AK; Massuger LF; van Hoesel RQ; Ottevanger PB
Eur J Cancer; 2013 Mar; 49(4):860-7. PubMed ID: 23099004
[TBL] [Abstract][Full Text] [Related]
2. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis.
Alifrangis C; Agarwal R; Short D; Fisher RA; Sebire NJ; Harvey R; Savage PM; Seckl MJ
J Clin Oncol; 2013 Jan; 31(2):280-6. PubMed ID: 23233709
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic evaluation of cisplatin, etoposide, and bleomycin chemotherapy regimen in high-risk gestational trophoblastic neoplasia].
Song SQ; Zhang GN
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):571-6. PubMed ID: 23141175
[TBL] [Abstract][Full Text] [Related]
4. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia.
Lurain JR; Schink JC
J Reprod Med; 2012; 57(5-6):219-24. PubMed ID: 22696816
[TBL] [Abstract][Full Text] [Related]
5. High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy.
Cagayan MS
J Reprod Med; 2012; 57(5-6):231-6. PubMed ID: 22696818
[TBL] [Abstract][Full Text] [Related]
6. Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia.
Even C; Pautier P; Duvillard P; Floquet A; Kerbrat P; Troalen F; Rey A; Balleyguier C; Tazi Y; Leary A; Augereau P; Morice P; Droz JP; Fizazi K; Lhommé C
Eur J Cancer; 2014 Aug; 50(12):2082-9. PubMed ID: 24910417
[TBL] [Abstract][Full Text] [Related]
7. [EMA/CO regimen for chemotherapy 24 patients with ultra high-risk gestational trophoblastic neoplasia].
Shen T; Chen LL; Qin JL; Wang XY; Cheng XD; Xie X; Lyu WG
Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):371-376. PubMed ID: 29961278
[No Abstract] [Full Text] [Related]
8. Management of drug resistant gestational trophoblastic neoplasia.
Patel SM; Desai A
J Reprod Med; 2010; 55(7-8):296-300. PubMed ID: 20795341
[TBL] [Abstract][Full Text] [Related]
9. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia.
Lurain JR; Nejad B
Gynecol Oncol; 2005 May; 97(2):618-23. PubMed ID: 15863169
[TBL] [Abstract][Full Text] [Related]
10. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.
Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ
J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528
[TBL] [Abstract][Full Text] [Related]
11. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen.
Mao Y; Wan X; Lv W; Xie X
Int J Gynaecol Obstet; 2007 Jul; 98(1):44-7. PubMed ID: 17481633
[TBL] [Abstract][Full Text] [Related]
12. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy.
Lurain JR; Singh DK; Schink JC
J Reprod Med; 2006 Oct; 51(10):767-72. PubMed ID: 17086804
[TBL] [Abstract][Full Text] [Related]
13. Clinical epidemiology and management of gestational trophoblastic neoplasia in Hungary in the past 34 years.
Fülöp V; Szigetvári I; Szepesi J; Végh G; Singh M; Berkowitz RS
J Reprod Med; 2012; 57(7-8):310-8. PubMed ID: 22838247
[TBL] [Abstract][Full Text] [Related]
14. Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia.
Rattanaburi A; Boonyapipat S; Supasinth Y
Asian Pac J Cancer Prev; 2015; 16(12):5037-41. PubMed ID: 26163637
[TBL] [Abstract][Full Text] [Related]
15. M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first-line treatment of high-risk gestational trophoblastic neoplasia.
Singh K; Gillett S; Ireson J; Hills A; Tidy JA; Coleman RE; Hancock BW; Winter MC
Int J Cancer; 2021 May; 148(9):2335-2344. PubMed ID: 33210289
[TBL] [Abstract][Full Text] [Related]
16. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy.
Escobar PF; Lurain JR; Singh DK; Bozorgi K; Fishman DA
Gynecol Oncol; 2003 Dec; 91(3):552-7. PubMed ID: 14675675
[TBL] [Abstract][Full Text] [Related]
17. Outcome of gestational trophoblastic neoplasia: experience from a tertiary cancer centre in India.
Gulia S; Bajpai J; Gupta S; Maheshwari A; Deodhar K; Kerkar RA; Seth V; Rekhi B; Menon S
Clin Oncol (R Coll Radiol); 2014 Jan; 26(1):39-44. PubMed ID: 24051171
[TBL] [Abstract][Full Text] [Related]
18. Treatment of high-risk gestational trophoblastic neoplasia with weekly high-dose methotrexate-etoposide.
Han SN; Amant F; Leunen K; Devi UK; Neven P; Berteloot P; Vergote I
Gynecol Oncol; 2012 Oct; 127(1):47-50. PubMed ID: 22705360
[TBL] [Abstract][Full Text] [Related]
19. EP-EMA regimen (etoposide and cisplatin with etoposide, methotrexate, and dactinomycin) in a series of 18 women with gestational trophoblastic neoplasia.
Han SN; Amant F; Leunen K; Devi UK; Neven P; Vergote I
Int J Gynecol Cancer; 2012 Jun; 22(5):875-80. PubMed ID: 22635033
[TBL] [Abstract][Full Text] [Related]
20. Plasma methotrexate levels in patients receiving etoposide, methotrexate, actinomycin, cyclophosphamide, and vincristine (EMA-CO) chemotherapy for trophoblastic neoplasia.
Kohorn EI
Gynecol Oncol; 1993 Sep; 50(3):300-4. PubMed ID: 8406191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]